PRESS RELEASE Astellas Pharma Inc.

The creation of Kanyos will enable preclinical advancement of products for type 1 diabetes and celiac disease. We are delighted our partner Astellas is certainly applying its assets and pharmaceutical development expertise to Anokion’s platform immunology and technology knowledge, through our new organization Kanyos, said Jeffrey A. Hubbell, Professor of Molecular Engineering at the University of Chicago, Professor of Bioengineering at the Ecole Polytechnique Fédérale de Lausanne, and the academic founder, Chief and Chairman Scientific Officer of both Anokion and Kanyos.They can come with tiny gold medals around their glass stems, just to remind users that they’re all winners! The bottom line in all this, of program, is that if you’re famous enough, the mainstream mass media will apologize FOR YOU. Party on!

Bloomberg examines potential benefits, drawbacks to PrEP ‘Gilead Sciences Inc. Based on the news service, the original outcomes of 10 trials including a lot more than 20,000 people could possibly be available as soon as July. ‘If the strategy functions, the supplements from Foster City, California-based Gilead may guarantee the global world a robust tool for fighting Helps, the deadliest infectious disease, after scientists’ failure up to now to develop a highly effective vaccine or virus-eliminating gel,’ Bloomberg writes.